Jupiter Neurosciences Names Jean Fallacara as Nugevia Brand Ambassador, Strengthens Longevity Supplement Line

Jupiter Neurosciences has appointed Jean Fallacara, a visionary entrepreneur and biohacker, as the third brand ambassador for its consumer longevity supplement line, Nugevia. Fallacara is known for pioneering advances in biohacking and biotechnology, and has founded and led multiple ventures. He believes Nugevia's products, which are built on the Company's patented resveratrol-based micellar delivery platform, JOTROL, represent the convergence of clinical research, biotechnology, and wellness innovation.

Jupiter Neurosciences (NASDAQ: JUNS), a clinical-stage pharmaceutical company, has appointed Jean Fallacara as the third brand ambassador for its consumer longevity supplement line, Nugevia™. Fallacara, a renowned entrepreneur and neuroscientist, brings extensive experience in biohacking and biotechnology to the role.

Jean Fallacara, recognized as one of the "Most Disruptive Entrepreneurs 2023," has founded and led multiple ventures, including Z-Sciences, which was acquired by inTEST Corp in 2021. He is also the founder of Lifespanning Media, a platform dedicated to extending and enriching human lifespan through science, art, health, and technology.

Nugevia™ is built on Jupiter's patented resveratrol-based micellar delivery platform, JOTROL™, which has demonstrated significantly enhanced bioavailability. The product line includes three formulations—GLO, MND, and PWR—designed to support cellular resilience. This consumer initiative is part of Jupiter's dual-path strategy, targeting the longevity market projected to reach $8 trillion by 2030, while supporting their clinical development programs.

The appointment of Fallacara strengthens Nugevia™'s launch, bringing clinical and scientific integrity to the fast-growing longevity space. Fallacara commented, "Resveratrol has always been an overlooked cornerstone of longevity, as essential as NAD or NMN. Nugevia™ takes this breakthrough molecule and finally unlocks its full potential, merging real science with wellness innovation to deliver energy, focus, and cellular health for anyone striving to live and perform at their best."

Nugevia™ is designed to support cognitive health, skin vitality, and cellular energy by leveraging the same clinically validated delivery technology used in Jupiter's therapeutic pipeline. The company's prescription pipeline includes a Phase IIa trial in Parkinson's disease, among other indications.

This strategic move reflects Jupiter's commitment to advancing clinically validated therapeutics while tapping into the rapidly growing longevity market. The consumer-facing arm is expected to create a revenue stream that supports ongoing clinical development, corporate operating costs, and enhances long-term shareholder value.

For more information, visit Jupiter Neurosciences' website at [www.jupiterneurosciences.com](http://www.jupiterneurosciences.com).